Protagonist Therapeutics, Inc - COMMON STOCK (PTGX)

Q2 2020 13F Holders as of 6/30/2020

Type / Class
Equity / COMMON STOCK
Shares outstanding
61.7M
Number of holders
80
Total 13F shares, excl. options
33.2M
Shares change
+10.9M
Total reported value, excl. options
$586M
Value change
+$211M
Number of buys
65
Number of sells
-27
Price
$17.66

Significant Holders of Protagonist Therapeutics, Inc - COMMON STOCK (PTGX) as of Q2 2020

97 filings reported holding PTGX - Protagonist Therapeutics, Inc - COMMON STOCK as of Q2 2020.
Protagonist Therapeutics, Inc - COMMON STOCK (PTGX) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 33.2M shares of 61.7M outstanding shares and own 53.82% of the company stock.
Largest 10 shareholders include FMR LLC (5.17M shares), RTW INVESTMENTS, LP (3.38M shares), FARALLON CAPITAL MANAGEMENT LLC (2.5M shares), Johnson & Johnson Innovation - JJDC, Inc. (2.45M shares), BVF INC/IL (2.37M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.2M shares), BlackRock Inc. (2.04M shares), BAKER BROS. ADVISORS LP (1.91M shares), VANGUARD GROUP INC (1.42M shares), and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.01M shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.